Uncategorized

Epicrispr, Infinimmune snag combined $165M in VC cash

Published

on

Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version